PYRIDAZINE-3-FORMAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

Title:

PYRIDAZINE-3-FORMAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

Document Type and Number:

WIPO Patent Application WO/2022/032484

Kind Code:

A1

Abstract:

Disclosed in the present invention are a pyridazine-3-formamide compound suitable for inhibiting or regulating the Janus kinase (JAK), in particular tyrosine kinase 2 (TYK2), and a preparation method therefor and the medical use thereof. In particular, disclosed in the present invention are a compound as represented by general formula (I) and a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof, a method for treating and/or preventing Janus kinase-mediated related diseases, in particular autoimmune diseases, inflammatory diseases and cancers, by means of using the compound or the pharmaceutically acceptable salt thereof, and a method for preparing the compound or the pharmaceutically acceptable salt thereof. Each substituent of general formula (I) has the same definition as that in the description.

More Like This:

JP2010522691	2-Hydroxy-1,3-diaminopropane derivative
JP4714139	Cardioprotective Delta Opioid Receptor Agonists and Their Usage
WO/2016/123530	COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICAL AGENTS

Inventors:

CHEN XIANGYANG (CN)
PANG YUCHENG (CN)

Application Number:

PCT/CN2020/108468

Publication Date:

February 17, 2022

Filing Date:

August 11, 2020

Export Citation:

Click for automatic bibliography generation Help

Assignee:

BEIJING INNOCARE PHARMA TECH CO LTD (CN)

International Classes:

A61K31/50; C07D237/24; A61K31/501; A61K31/5377; A61K31/541; A61P1/00; A61P1/04; A61P1/16; A61P3/10; A61P5/14; A61P7/06; A61P9/10; A61P11/06; A61P13/12; A61P15/00; A61P17/00; A61P17/04; A61P17/06; A61P17/14; A61P19/02; A61P21/04; A61P25/14; A61P25/16; A61P25/28; A61P27/02; A61P29/00; A61P35/00; A61P35/02; A61P37/02; A61P37/06; A61P37/08; C07D401/12; C07D401/14; C07D403/12; C07D403/14; C07D405/12; C07D405/14; C07D409/12; C07D413/14

Domestic Patent References:

WO2020156311A1	2020-08-06
WO2020086616A1	2020-04-30
WO2007011721A1	2007-01-25
WO2002022605A1	2002-03-21

Foreign References:

CN110818641A	2020-02-21
CN104470363A	2015-03-25
CN105960404A	2016-09-21
CN103201277A	2013-07-10

Other References:

LUCAS, MATTHEW C. ET AL.: "Using Ovality to Predict Nonmutagenic, Orally Efficacious Pyridazine Amides as Cell Specific Spleen Tyrosine Kinase Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 6, 12 February 2014 (2014-02-12), pages 2683 - 2691, XP055583549, ISSN: 0022-2623, DOI: 10.1021/jm401982j

Download PDF:

View/Download PDF PDF Help

Previous Patent: METHOD FOR MEASURING AND CALCULATING FLUE GAS MAIN CONTROL TEMPERATURE OF FIRST FLUE OF GARBAGE INCI...

Next Patent: APPARATUS AND METHOD FOR BEAM BASED POSITIONING OF USER EQUIPMENT BY MMW SMALL CELL